tbuckley/cabot-search huggingface dataset:
Young adult cancer survivors' (CS) follow-up care expectations of their primary care providers (PCPs) and oncologists.
Authors: Divjot Singh Kumar, Ali Moghaddamjou, Winson Y. Cheung
Journal: Journal of Clinical Oncology (2013)

9598 Background: The delivery of cancer survivorship care can be complicated by a lack of clarity surrounding physician roles during follow-up. This can be particularly challenging for young adult CS who face unique needs. Our aim was to characterize young CS’ follow-up care expectations of their PCPs and oncologists. Methods: A self-administered survey was mailed to all CS diagnosed with cancer from 2005 to 2009, aged 20 to 39 years at the time of diagnosis, evaluated at any 1 of 5 regional cancer centers in British Columbia, and lived beyond 2 years. The questionnaire focused on demographics, prior treatment, and CS attitudes regarding physician responsibilities during survivorship, specifically their views about their PCPs’ and oncologists’ roles. Descriptive statistics and regression analyses were used to summarize these expectations and to determine if they differed based on physician type. Results: A total of 426 patients were included (response rate 59%): current median age was 40 years (range 24-45) and 301 (71%) were women. Common tumor sites were breast (48%), testicular (27%), and gynecological (18%). Most patients (63 and 65%, respectively) expected PCPs to be responsible for following their most recent cancer and screening for future cancers. Nearly all (85 and 93%, respectively) indicated that PCPs should also provide preventive care and manage their co-morbidities. Conversely, a significant proportion (65%) felt that oncologists should remain responsible for addressing side effects of cancer treatments throughout survivorship. In terms of fertility discussions, half of patients viewed this as a role for oncologists whereas the remainder perceived this to be more suitable for PCPs. Interestingly, neither PCPs nor oncologists were seen to have any significant role in addressing social reintegration, interpersonal relationships, or sexual function, with &lt;30% of respondents expecting these to be discussed by either physician. Conclusions: Young adult CS expect PCPs to be responsible for most aspects of their ongoing care. More clarity regarding physician roles is required with respect to specific survivorship issues, such as fertility, sexual function and psychosocial health.
Construct validity and reliability of the Brazilian version of the Falls Efficacy Scale in patients with COPD
Authors: C.F. Scremim, B.F.P.M.C. Simões, J.A. de Barros, S. Valderramas
Journal: Pulmonology (2020)

The Brazilian version of Falls Efficacy Scale (FES-BR) used to assess the fear of falling, has not yet been validated in patients with Chronic Obstructive Pulmonary Disease (COPD). The aim of the present study was to investigate the construct validity and reliability of the (FES-BR) in patients with COPD. A cross-sectional study involving subjects with COPD, aged between 48 and 83 years. Data were collected by two independent and blind assessors. Construct validity was assessed using the Spearman's rank correlation coefficient between FES-BR and Berg Balance Scale, Downton fall risk index, Timed Up and Go Test (TUG), hand-grip strength (HGS), Five Times Sit to Stand Test (FTSST) and 6-Minute Walk Test (6MWT). Reliability was measured by the Cronbach's alpha coefficient, Intraclass Correlation Coefficient (ICC), and Bland-Altman plot. The study included 60 subjects aged 68.3 ± 9.9 years and FEV1 56.0 ± 19.3. The correlations were significantly strong between FES-BR and the Berg Balance Scale (r = −0.66), TUG (r = 0.64), HGS (r = 0.61) and FTSST (r = 0.62); and moderate between FES-BR and the Downton fall risk index (r = 0.38) and the 6MWT (r = −0.48). All correlations had p < 0.001. Intra-rater [ICC = 0.94, (95% CI = 0.91–0.96)] and inter-rater [0.97, (95% CI = 0.97–0.98)] reliability were considered excellent. The Brazilian version of FES was valid and reliable in assess fear of falling in subjects with COPD.
INCIDENT PARAVALVULAR REGURGITATION AND CLINICAL OUTCOMES IN PATIENTS UNDERGOING TRANSAORTIC VALVE REPLACEMENT WITH TTE VS. TEE PERIPROCEDURAL IMAGING GUIDANCE
Authors: Sindhura Ananthaneni, Mackram Eleid, Rosalyn Adigun, Vuyisile Tlhopane Nkomo, Sorin Pislaru, Jae K. Oh, Juan Crestanello, Gurpreet Sandhu, Charanjit S. Rihal, Kevin Greason, Jeremy Thaden
Journal: Journal of the American College of Cardiology (2020)
Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study
Authors: Heinz Reichmann, Andrew Lees, José-Francisco Rocha, Diogo Magalhães, Patrício Soares-da-Silva
Journal: Translational Neurodegeneration (2020)

Abstract Background The efficacy and safety of opicapone, a once-daily catechol-O-methyltransferase inhibitor, have been established in two large randomized, placebo-controlled, multinational pivotal trials. Still, clinical evidence from routine practice is needed to complement the data from the pivotal trials. Methods OPTIPARK (NCT02847442) was a prospective, open-label, single-arm trial conducted in Germany and the UK under clinical practice conditions. Patients with Parkinson’s disease and motor fluctuations were treated with opicapone 50 mg for 3 (Germany) or 6 (UK) months in addition to their current levodopa and other antiparkinsonian treatments. The primary endpoint was the Clinician’s Global Impression of Change (CGI-C) after 3 months. Secondary assessments included Patient Global Impressions of Change (PGI-C), the Unified Parkinson’s Disease Rating Scale (UPDRS), Parkinson’s Disease Questionnaire (PDQ-8), and the Non-Motor Symptoms Scale (NMSS). Safety assessments included evaluation of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs). Results Of the 506 patients enrolled, 495 (97.8%) took at least one dose of opicapone. Of these, 393 (79.4%) patients completed 3 months of treatment. Overall, 71.3 and 76.9% of patients experienced any improvement on CGI-C and PGI-C after 3 months, respectively (full analysis set). At 6 months, for UK subgroup only ( n = 95), 85.3% of patients were judged by investigators as improved since commencing treatment. UPDRS scores at 3 months showed statistically significant improvements in activities of daily living during OFF (mean ± SD change from baseline: − 3.0 ± 4.6, p &lt; 0.0001) and motor scores during ON (− 4.6 ± 8.1, p &lt; 0.0001). The mean ± SD improvements of − 3.4 ± 12.8 points for PDQ-8 and -6.8 ± 19.7 points for NMSS were statistically significant versus baseline (both p &lt; 0.0001). Most of TEAEs (94.8% of events) were of mild or moderate intensity. TEAEs considered to be at least possibly related to opicapone were reported for 45.1% of patients, with dyskinesia (11.5%) and dry mouth (6.5%) being the most frequently reported. Serious TEAEs considered at least possibly related to opicapone were reported for 1.4% of patients. Conclusions Opicapone 50 mg was effective and generally well-tolerated in PD patients with motor fluctuations treated in clinical practice. Trial registration Registered in July 2016 at clinicaltrials.gov ( NCT02847442 ).
LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS, STATIN THERAPY, AND THE INCIDENCE OF PLAQUE RUPTURE
Authors: Osamu Kurihara, Hyung Oh Kim, Michele Russo, Makoto Araki, Akihiro Nakajima, Hang Lee, Masamichi Takano, Kyoichi Mizuno, Ik-Kyung Jang
Journal: Journal of the American College of Cardiology (2020)
Opportunity for all? Socioeconomic disparities in chemotherapy (CT) use for metastatic prostate cancer (mPC).
Authors: Daniella Perlroth, Yesenia L Luna, Stephen F Thompson, Muralikrishna Tangirala, Daniel B Ng, Leonardo Nicacio, Darius Lakdawalla
Journal: Journal of Clinical Oncology (2012)

e15186 Background: CT for mPC is a category 1 recommendation after progression despite hormone therapy (NCCN Clinical Guidelines in Oncology). Having previously documented large regional variations in CT use (Perlroth et al, GU-ASCO, Feb 2-4, 2012), we sought to determine if such disparities exist for patients across socioeconomic status (SES) indicators. Methods: Using Surveillance, Epidemiology, and End Results data linked to Medicare claims, we identified all men diagnosed between 2000 and 2007 with mPC initiated on hormones, excluding patients not continuously enrolled in Medicare Parts A/B or diagnosed with other cancers. We used logistic regression to estimate probability of CT, adjusting for demographic, SES, grade stage and PSA of cancer, and other comorbidities, and tested alternative measures of SES in sensitivity analyses. We report odds ratios (OR) for CT use by socioeconomic status, 95% confidence intervals (CI), and estimates for differences in CT use for high and low SES patients. Results: 7852 patients were in the cohort, mean and median age of 76 and 74 years. 19% advanced to CT, but patients living in regions below the federal poverty level were significantly less likely to do so (OR=0.85, 95% CI: 0.73-0.98). Patients in regions in the bottom quartile of education exhibited OR=0.67 (95% CI: 0.57-0.80) compared with the top quartile. Black race, education, and income factors were not associated with CT use. There were no significant interactions between race and education or income. Median-aged patients residing in the highest-quartile areas versus lowest for education had an estimated 6% higher absolute probability of advancing to CT. After controlling for poverty and education, black race conferred an additional 1% nonsignificant lower probability of advancing to CT over nonblacks. Treatment disparities between groups remained stable during 2000-2007. Conclusions: Education status was the strongest predictor of CT initiation in men with mPC. Poverty and black race also predicted lower CT use. Given that all men in this study were enrolled in Medicare, efforts and research to reduce treatment disparities may need to focus on health system needs serving low socioeconomic communities.
CALLING FOR SUPPORT: EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) ASSISTED HIGH RISK PERCUTANEOUS CORONARY INTERVENTION OF MULTIVESSEL CORONARY ARTERY DISEASE
Authors: Hasan Rehman, Apurva Patel, Michael McArdle, Joggy George, Jorge Escobar, Samar Sheth, Salman Bandeali
Journal: Journal of the American College of Cardiology (2020)
LEFT ATRIAL APPENDAGE SEAL FOLLOWING PERCUTANEOUS LEFT ATRIAL APPENDAGE OCCLUSION
Authors: Susie Sennhauser, Demilade Adedinsewo, Salwa Najiyah, Jeffrey Winder, Salman Farhat, K. Venkatachalam, Peter Pollak, Pragnesh Parikh
Journal: Journal of the American College of Cardiology (2020)
A phase II study of dasatinib therapy in children and adolescents with newly diagnosed chronic phase chronic myelogenous leukemia (CML-CP) or Philadelphia chromosome-positive (Ph+) leukemias resistant or intolerant to imatinib.
Authors: Michel Zwaan, Linda C. Stork, Yves Bertrand, Lia Gore, Nobuko Hijiya, Carmino De Souza, Maria Lucia de Martino Lee, M. Brigid Bradley-Garelik, Pamela Kearns
Journal: Journal of Clinical Oncology (2012)

TPS9594 Background: Dasatinib is a BCR-ABL inhibitor approved for treatment in adult patients (pts) with newly diagnosed Ph+ CML-CP; CML resistant/intolerant to prior therapy, including imatinib; and Ph+ acute lymphoblastic leukemia (ALL). There are no established dasatinib treatment regimens for children/adolescents with relapsed/refractory leukemia, but pediatric trials are underway. A phase I dose-escalation study of dasatinib in pediatric pts with refractory solid tumors (n=28) and imatinib-refractory, Ph+ leukemia (n=11) reported a maximum tolerated dose of 85 mg/m 2 twice daily in solid-tumor pts and at least a partial cytogenetic response (CyR) in all evaluable CML pts (n=9) (Aplenc, J Clin Oncol 2011). Preliminary results from a phase I dose-escalation study in pediatric pts with subtypes of relapsed/refractory leukemia (NCT00306202) indicate that dasatinib was well tolerated up to 120 mg/m 2 (Zwaan, Blood 2010 [abstr 2265]). Further study of dasatinib in pediatric pts is warranted. Methods: To evaluate the safety and efficacy of dasatinib monotherapy in children/adolescents with newly diagnosed CML-CP or Ph+ leukemias resistant/intolerant to imatinib, a phase II nonrandomized, global study of dasatinib in pts birth to &lt;18 y is ongoing (NCT00777036): Cohort 1 (C1), Ph+ CML-CP pts resistant/intolerant to imatinib; Cohort 2 (C2), Ph+ ALL, accelerated or blast phase CML pts resistant/intolerant to or relapsed after imatinib therapy; or Cohort 3 (C3), newly diagnosed, treatment-naïve Ph+ CML-CP pts. Treatments are once daily with dasatinib 60 mg/m 2 (C1/C3) or 80 mg/m 2 (C2) for ≥24 months. Primary endpoints are major CyR (C1), complete hematologic response (C2), and complete CyR (C3). Secondary endpoints include safety, tolerability, best response, time to/duration of response, survival, and molecular response rates. BCR-ABL mutations are evaluated. First patient first visit was March 2009; estimated trial completion is September 2016. As of January 2012, 63 pts (n=27 aged &lt;12 y; n=36 aged ≥12 y) have been treated in C1/C2 (n=41) and C3 (n=22). Enrollment is ongoing at 79 sites.
Roles of circRNAs in the tumour microenvironment
Authors: Qiuge Zhang, Weiwei Wang, Quanbo Zhou, Chen Chen, Weitang Yuan, Jinbo Liu, Xiaoli Li, Zhenqiang Sun
Journal: Molecular Cancer (2020)

Abstract The tumour microenvironment (TME) constitutes the area surrounding the tumour during its development and has been demonstrated to play roles in cancer-related diseases through crosstalk with tumour cells. Circular RNAs (circRNAs) are a subpopulation of endogenous noncoding RNAs (ncRNAs) that are ubiquitously expressed in eukaryotes and have multiple biological functions in the regulation of cancer onset and progression. An increasing number of studies have shown that circRNAs participate in the multifaceted biological regulation of the TME. However, details on the mechanisms involved have remained elusive until now. In this review, we analyse the effects of circRNAs on the TME from various perspectives, including immune surveillance, angiogenesis, hypoxia, matrix remodelling, exo-circRNAs and chemoradiation resistance. Currently, the enormous potential for circRNA use in targeted therapy and as noninvasive biomarkers have drawn our attention. We emphasize the prospect of targeting circRNAs as an essential strategy to regulate TME, overcome cancer resistance and improve therapeutic outcomes.
Autologous heterotopic transplant of peripheral blood associated to chemotherapy as immunotherapy of solid tumors.
Authors: Eduardo M. Lasalvia-Prisco, Pablo Goldschmidt, Felipe Galmarini, Jesus Vazquez, Eduardo E. Lasalvia-Galante, Wilson Golomar, Silvia Cucchi
Journal: Journal of Clinical Oncology (2012)

e13105 Background: Successive developed configurations of Autologous Heterotopic Transplant of Peripheral Blood (AHTOPB) were reported lately. In advanced stages of different primary tumors, AHTOPB has improved the antitumoral effect of chemotherapy (CH). A cohort of patients (pts) was selected from these trials to explore the biological response modifications (angiogenesis, immunity) associated to such antitumoral effect. Methods: From 6 reported 2-arm trials (CH and AHTOPB+CH treated), 60 pts were selected, 5 from each arm and trial. Trials referred to Breast, NSC Lung, prostate, ovary, pancreas, colon. Inclusion criteria: histology confirmed, M1 stage, unresectable, measurable according Response Evaluation Criteria in Solid Tumors (RECIST), PS 0-2 according Eastern Cooperative Oncology Group (ECOG), not previous CH, organic functions preserved. Exclusion criteria: brain M1, treated comorbility, additional antitumor treatment. AHTOPB procedure as it was described: 1) Cyclophosphamide low dose, 2) Immunization site conditioning with activated autologous blood, 3) Immunization with tumor antigens released to the blood inside heat shock proteins. CH: standard first line recommended for each tumor. Assessments. In venous blood sample pre/post treatment: T-Regulatory cells (T-Reg); Activated Dendritic cells (aDC); Lymphocyte Proliferative Index AHTOPB challenged (LPI); Angiostatin (AT); Interleukine-2 (IL2); Interleukine-12 (IL12); Gamma Interferon (G-If). In sentinel lymph-node of immunization site post AHTOPB treatment: T-Reg and aDC. In clinical follow up: 30-day Tumor Growth (TG) according RECIST; Disease control rate (DCR), Overall Survival (OS), Toxicities (Tx) according NCI (≥3). Measurements were expressed as % of pretreatment mean value in same primary tumor; % of 2 treatments were statistically compared using two tailed Student T-test. Results: Arm AHTOPB+CH, comparable to arm CH, evidenced significant decrease T-Reg, VEGF, TG, and increase aDC, LPI, AT, IL2, IL12, G-If, DCR. No significant different toxicity. Conclusions: In cancer pts, ATHOPB+CH elicits the conditioning to produce biological responses compatible with antitumor immunotherapy.
Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab
Authors: Anna Minchom, Wei Yuan, Mateus Crespo, Bora Gurel, Ines Figueiredo, Andrew Wotherspoon, Susana Miranda, Ruth Riisnaes, Ana Ferreira, Claudia Bertan, Rita Pereira, Matt Clarke, Chloe Baker, Joo Ern Ang, Nicos Fotiadis, Nina Tunariu, Suzanne Carreira, Sanjay Popat, Mary O'Brien, Udai Banerji, Johann de Bono, Juanita Lopez
Journal: Journal for ImmunoTherapy of Cancer (2020)

Background This case represents an exceptional response to pembrolizumab in a patient with epithelioid mesothelioma with a further response on rechallenge. Case presentation A 77-year-old woman with advanced epithelioid mesothelioma extensively pretreated with chemotherapy demonstrated a prolonged response of 45 months to 52 cycles of pembrolizumab. On rechallenge with pembrolizumab, further disease stability was achieved. Serial biopsies and analysis by immunohistochemistry and immunofluorescence demonstrated marked immune infiltration and documented the emergency of markers of immune exhaustion. Whole exome sequencing demonstrated a reduction in tumor mutational burden consistent with subclone elimination by immune checkpoint inhibitor (CPI) therapy. The relapse biopsy had missense mutation in BTN2A1. Conclusion This case supports rechallenge of programme death receptor 1 inhibitor in cases of previous CPI sensitivity and gives molecular insights.
IMPACT OF A HISTORY OF ATRIAL FIBRILLATION ON THE MECHANISM OF MITRAL REGURGITATION, PROGNOSIS AND TREATMENT EFFECTS OF THE MITRACLIP: THE COAPT TRIAL
Authors: Zachary Gertz, Howard Herrmann, Scott Lim, Saibal Kar, None Kar, Samir R. Kapadia, Grant W. Reed, Rishi Puri, Amar Krishnaswamy, Bernard J. Gersh, Neil J. Weissman, Federico M. Asch, Ioanna Kosmidou, Zixuan Zhang, William Abraham, JoAnn Lindenfeld, Gregg W. Stone, Michael Mack
Journal: Journal of the American College of Cardiology (2020)
Elevated CSF-1 serum concentrations to predict lymph node metastasis and overall survival in women with early breast cancer.
Authors: Christian F. Singer, Seyedhossein Aharinejad, Mohamed Salama, Karin Zins, Patrick Paulus, Andreas Berger
Journal: Journal of Clinical Oncology (2013)

11032 Background: Colony-stimulating factor-1 (CSF1) is a key modulator of tissue macrophages and contributes to the physiological function of the mammary gland. It has, however, also been associated with breast cancer since expression of its receptor CSF-1R is a strong predictor of poor outcome in early breast cancer and results in tumor cell invasiveness and pro-metastatic behavior in vitro. Methods: We have prospectively measured circulating CSF-1 with ELISA in 572 women with early breast cancer and in 688 women with benign breast lesions; and correlated these values with overall survival, nodal status and other clinical and histological parameters. Results: Serum CSF-1 concentrations were significantly elevated in patients with early breast cancer when compared to those with benign tumors (p&lt;0.0001). Within breast cancer patients, CSF-1 was higher in women with involved axillary lymph nodes (p=0.04). CSF-1 concentrations were correlated with tumor size (p=0.002), age (p&lt;0.001), and Ki67 expression (p=0.006). Log CSF-1 serum concentrations were predictive of poor survival in both univariate (HR: 3.77, CI: 1.65-8.65, p=0.002) and multivariate analyses (HR: 3.1, CI: 1.03-9.33, p=0.04). Post- but not premenopausal women with CSF-1 serum concentrations &gt;873 pg/ml experienced a significantly poorer outcome (p=0.004 log rank test). Conclusions: CSF1 serum concentrations are elevated in women with malignant breast tumors. In early breast cancer, elevated serum CSF-1 is associated with nodal involvement, and in postmenopausal women also with poor overall survival.
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
Authors: Vicky Makker, Matthew H. Taylor, Carol Aghajanian, Ana Oaknin, James Mier, Allen L. Cohn, Margarita Romeo, Raquel Bratos, Marcia S. Brose, Christopher DiSimone, Mark Messing, Daniel E. Stepan, Corina E. Dutcus, Jane Wu, Emmett V. Schmidt, Robert Orlowski, Pallavi Sachdev, Robert Shumaker, Antonio Casado Herraez
Journal: Journal of Clinical Oncology (2020)

Patients with advanced endometrial carcinoma have limited treatment options. We report final primary efficacy analysis results for a patient cohort with advanced endometrial carcinoma receiving lenvatinib plus pembrolizumab in an ongoing phase Ib/II study of selected solid tumors.
Benzene-poly-carboxylic acids complex with Cis-diammineplatinum (II) dichloride (BP-C1), a novel anticancer agent, induces apoptosis in human breast cancer cells through caspase activation.
Authors: Fuad Fares, Basem Fares, Stig Larsen, Steen Lindkair-Jensen
Journal: Journal of Clinical Oncology (2013)

e12029 Background: Breast cancer is the most frequent malignancy in women in western countries and despite progress in the treatment options surgery, radiation, chemotherapy and hormonal therapy it is still the leading cause of cancer death. BP-C1 is a novel anti-cancer complex of benzol-polycarbonic acids with ammonium-platinum salt developed by Meabco ltd, Denmark. Methods: In the present study, the effect of BP-C1 on growth of human breast cancer cells, MCF7 and T47D, was studied. Cells were exposed to different doses of BP-C1, 100-1000 µg/ml, and cell viability, toxicity (LDH release), cell cycle, apoptosis, caspase activation and gene expression were examined. Results: No toxicity was observed. Exposure of the cells to BP-C1 for 48h, significantly (P&lt;0.001) reduced cell viability by approxematly 90% with IC50 of 400 µg/ml. In cell cycle studies cells were accumulated in sub-G1 phase, which may indicate induction of apoptosis. Annexin 5 assay demonstrated that BP-C1 induces apoptosis of MCF-7 and T47D cell by 65% and 34%, respectively, after 48h of treatment. Detection of caspases by western blot analysis revealed that BP-C1 activates caspase 8 and caspase 9. Moreover, gene expression experiments following BP-C1 treatment and using the Applied Biosystems TaqMan Array Plates indicated that BP-C1 caused an increase in the the expression of pro-apoptotic genes; CASP8AP2, TNFRSF21, RELB, NFKB2, BIRC8 and FADD when compared to the expression level of the House keeping genes, HPRT1 and GAPDH. On the other hand, lower levels of mRNA transcripts of the inhibitory apoptotic genes; BCL2L2 and XIAP were detected. Conclusions: These results may indicate that BP-C1 reduced cell viability of human cancer cells by a unigue induction of apoptosis through activation of the extrinsic (death receptors) and the intrinsic (mitochondrion) apoptotic pathways. These findings may lead to the development of new therapeutic strategies for treatment of cancer using BP-C1 or analogs.
Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial
Authors: Wing Ho Man, Nienke M Scheltema, Melanie Clerc, Marlies A van Houten, Elisabeth E Nibbelke, Niek B Achten, Kayleigh Arp, Elisabeth A M Sanders, Louis J Bont, Debby Bogaert
Journal: The Lancet Respiratory Medicine (2020)